The Experts below are selected from a list of 3879 Experts worldwide ranked by ideXlab platform

Zain I. Khalpey - One of the best experts on this subject based on the ideXlab platform.

  • a dual therapy of off pump temporary left ventricular extracorporeal device and Amniotic Stem Cell for cardiogenic shock
    Journal of Cardiothoracic Surgery, 2017
    Co-Authors: Toshinobu Kazui, Phat L. Tran, Tia R. Pilikian, John Konhilas, Katie Marsh, Raymond B Runyan, Richard G Smith, Zain I. Khalpey
    Abstract:

    Temporary mechanical circulatory support device without sternotomy has been highly advocated for severe cardiogenic shock patient but little is known when coupled with Amniotic Stem Cell therapy. This case reports the first dual therapy of temporary left ventricular extracorporeal device CentriMag with distal banding technique and human Amniotic Stem Cell injection for treating a severe refractory cardiogenic shock of an 68-year-old female patient. A minimally-invasive off-pump LVAD was established by draining from the left ventricle and returning to the right axillary artery with distal arterial banding to prevent right upper extremity hyperperfusion. Amniotic Stem Cells were injected intramyocardially at the left ventricular apex, lateral wall, inferior wall, and right subclavian vein. The concomitant use of the temporary minimally-invasive off-pump CentriMag placement and Stem Cell therapy not only provided an alternative to cardiopulmonary bypass and full-median sternotomy procedures but may have also synergistically enhanced myocardial reperfusion and regeneration.

  • A dual therapy of off-pump temporary left ventricular extracorporeal device and Amniotic Stem Cell for cardiogenic shock
    BMC, 2017
    Co-Authors: Toshinobu Kazui, Phat L. Tran, Tia R. Pilikian, Katie M. Marsh, Raymond Runyan, John Konhilas, Richard Smith, Zain I. Khalpey
    Abstract:

    Abstract Background Temporary mechanical circulatory support device without sternotomy has been highly advocated for severe cardiogenic shock patient but little is known when coupled with Amniotic Stem Cell therapy. Case presentation This case reports the first dual therapy of temporary left ventricular extracorporeal device CentriMag with distal banding technique and human Amniotic Stem Cell injection for treating a severe refractory cardiogenic shock of an 68-year-old female patient. A minimally-invasive off-pump LVAD was established by draining from the left ventricle and returning to the right axillary artery with distal arterial banding to prevent right upper extremity hyperperfusion. Amniotic Stem Cells were injected intramyocardially at the left ventricular apex, lateral wall, inferior wall, and right subclavian vein. Conclusion The concomitant use of the temporary minimally-invasive off-pump CentriMag placement and Stem Cell therapy not only provided an alternative to cardiopulmonary bypass and full-median sternotomy procedures but may have also synergistically enhanced myocardial reperfusion and regeneration

James J Yoo - One of the best experts on this subject based on the ideXlab platform.

  • isolation of Amniotic Stem Cell lines with potential for therapy
    Obstetrical & Gynecological Survey, 2007
    Co-Authors: Paolo De Coppi, Laura Perin, Georg Bartsch, Minhaj M Siddiqui, Cesar C Santos, Gustavo Mostoslavsky, Angeline C Serre, Evan Y Snyder, James J Yoo, Mark E Furth
    Abstract:

    Amniotic fluid contains multiple Cell types derived from the developing fetus, including some that can give rise to differentiated adipose, muscle, bone, and neuronal Cell lines. The present investigators have identified lines of broadly multipotent Amniotic fluid-derived Stem (AFS) Cells that can give rise to a wide range of lineages including those in all embryonic germ layers, thereby meeting the criterion for pluripotent Stem Cells. Immunoselection with magnetic microspheres was used to isolate, from cultures of human amniocentesis specimens taken for prenatal genetic diagnosis, Cells bearing the surface antigen c-Kit, the receptor for Stem Cell factor. Flow cytometry served to assess markers expressed by human AFS Cells. AFS Cells from 19 amniocentesis donors were able to differentiate along adipogenic, osteogenic, myogenic, endothelial, neurogenic, and hepatic pathways. Induced differentiation along multiple pathways was documented by the expression of mRNAs for lineage-specific genes. Multilineage differentiation was characteristic of AFS Cells that were cloned by limiting dilution. Studies based on marking with a retroviral vector confirmed that cloned AFS Cells and their differentiated derivatives did in fact descend from a single Cell, and that the AFS Cells are pluripotent Stem Cells. Feeders were not necessary for the undifferentiated AFS Cells to expand extensively. The Cells doubled in 36 hours and were not tumorigenic. Lines maintained for more than 250 population doublings continued to have long telomeres and normal karyotypes. The differentiated Cells derived from AFS Cells included neuronal lineage Cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage Cells producing urea, and osteogenic lineage Cells that formed tissue-engineered bone. These studies affirm that Stem Cells capable of extensive self-renewal can routinely be obtained from human Amniotic fluid. AFS Cells can serve as precursors to a broad range of differentiated Cell types that potentially have therapeutic applications. Banking of Cells that would otherwise be discarded could provide a convenient source not only for autologous treatment later in life, but for matching of histocompatible donor Cells with prospective recipients.

  • isolation of Amniotic Stem Cell lines with potential for therapy
    Nature Biotechnology, 2007
    Co-Authors: Paolo De Coppi, Laura Perin, Georg Bartsch, Minhaj M Siddiqui, Tao Xu, Cesar C Santos, Gustavo Mostoslavsky, Angeline C Serre, Evan Y Snyder, James J Yoo
    Abstract:

    Stem Cells capable of differentiating to multiple lineages may be valuable for therapy. We report the isolation of human and rodent Amniotic fluid‐derived Stem (AFS) Cells that express embryonic and adult Stem Cell markers. Undifferentiated AFS Cells expand extensively without feeders, double in 36 h and are not tumorigenic. Lines maintained for over 250 population doublings retained long telomeres and a normal karyotype. AFS Cells are broadly multipotent. Clonal human lines verified by retroviral marking were induced to differentiate into Cell types representing each embryonic germ layer, including Cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. Examples of differentiated Cells derived from human AFS Cells and displaying specialized functions include neuronal lineage Cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage Cells producing urea, and osteogenic lineage Cells forming tissue-engineered bone. Amniotic fluid is known to contain multiple Cell types derived from the developing fetus 1,2 . Cells within this heterogeneous population can give rise to diverse differentiated Cells including those of adipose, muscle, bone and neuronal lineages 3‐6 . We now describe lines of broadly multipotent AFS Cells, and use retroviral marking to verify that clonal human AFS Cells can give rise to adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic lineages, inclusive of all embryonic germ layers. In this respect, they meet a commonly accepted criterion for pluripotent Stem Cells, without implying that they can generate every adult tissue. Neurons, hepatocytes and osteoblasts are among the Cell types for which improved Stem Cell sources may open up novel therapeutic applications. For each of these examples we show that AFS Cells can yield differentiated Cells that express lineage-specific markers and acquire characteristic functions in vitro. In addition, we present initial studies indicating that AFS Cells induced toward particular lineages can generate specialized Cells after implantation in vivo .W e show that AFS Cells directed to neural lineage differentiation by exposure to nerve growth factor (NGF) are able to widely engraft the developing mouse brain in a manner similar to that observed previously for neural Stem Cells 7 . In addition, we document the formation of tissueengineered bone from printed constructs of osteogenically differentiated human AFS Cells in immune-deficient mice. RESULTS Clonal Stem Cell lines from Amniotic fluid Approximately 1% of the Cells in cultures of human amniocentesis specimens obtained for prenatal genetic diagnosis express the surface

Toshinobu Kazui - One of the best experts on this subject based on the ideXlab platform.

  • a dual therapy of off pump temporary left ventricular extracorporeal device and Amniotic Stem Cell for cardiogenic shock
    Journal of Cardiothoracic Surgery, 2017
    Co-Authors: Toshinobu Kazui, Phat L. Tran, Tia R. Pilikian, John Konhilas, Katie Marsh, Raymond B Runyan, Richard G Smith, Zain I. Khalpey
    Abstract:

    Temporary mechanical circulatory support device without sternotomy has been highly advocated for severe cardiogenic shock patient but little is known when coupled with Amniotic Stem Cell therapy. This case reports the first dual therapy of temporary left ventricular extracorporeal device CentriMag with distal banding technique and human Amniotic Stem Cell injection for treating a severe refractory cardiogenic shock of an 68-year-old female patient. A minimally-invasive off-pump LVAD was established by draining from the left ventricle and returning to the right axillary artery with distal arterial banding to prevent right upper extremity hyperperfusion. Amniotic Stem Cells were injected intramyocardially at the left ventricular apex, lateral wall, inferior wall, and right subclavian vein. The concomitant use of the temporary minimally-invasive off-pump CentriMag placement and Stem Cell therapy not only provided an alternative to cardiopulmonary bypass and full-median sternotomy procedures but may have also synergistically enhanced myocardial reperfusion and regeneration.

  • A dual therapy of off-pump temporary left ventricular extracorporeal device and Amniotic Stem Cell for cardiogenic shock
    BMC, 2017
    Co-Authors: Toshinobu Kazui, Phat L. Tran, Tia R. Pilikian, Katie M. Marsh, Raymond Runyan, John Konhilas, Richard Smith, Zain I. Khalpey
    Abstract:

    Abstract Background Temporary mechanical circulatory support device without sternotomy has been highly advocated for severe cardiogenic shock patient but little is known when coupled with Amniotic Stem Cell therapy. Case presentation This case reports the first dual therapy of temporary left ventricular extracorporeal device CentriMag with distal banding technique and human Amniotic Stem Cell injection for treating a severe refractory cardiogenic shock of an 68-year-old female patient. A minimally-invasive off-pump LVAD was established by draining from the left ventricle and returning to the right axillary artery with distal arterial banding to prevent right upper extremity hyperperfusion. Amniotic Stem Cells were injected intramyocardially at the left ventricular apex, lateral wall, inferior wall, and right subclavian vein. Conclusion The concomitant use of the temporary minimally-invasive off-pump CentriMag placement and Stem Cell therapy not only provided an alternative to cardiopulmonary bypass and full-median sternotomy procedures but may have also synergistically enhanced myocardial reperfusion and regeneration

Paolo De Coppi - One of the best experts on this subject based on the ideXlab platform.

  • isolation of Amniotic Stem Cell lines with potential for therapy
    Obstetrical & Gynecological Survey, 2007
    Co-Authors: Paolo De Coppi, Laura Perin, Georg Bartsch, Minhaj M Siddiqui, Cesar C Santos, Gustavo Mostoslavsky, Angeline C Serre, Evan Y Snyder, James J Yoo, Mark E Furth
    Abstract:

    Amniotic fluid contains multiple Cell types derived from the developing fetus, including some that can give rise to differentiated adipose, muscle, bone, and neuronal Cell lines. The present investigators have identified lines of broadly multipotent Amniotic fluid-derived Stem (AFS) Cells that can give rise to a wide range of lineages including those in all embryonic germ layers, thereby meeting the criterion for pluripotent Stem Cells. Immunoselection with magnetic microspheres was used to isolate, from cultures of human amniocentesis specimens taken for prenatal genetic diagnosis, Cells bearing the surface antigen c-Kit, the receptor for Stem Cell factor. Flow cytometry served to assess markers expressed by human AFS Cells. AFS Cells from 19 amniocentesis donors were able to differentiate along adipogenic, osteogenic, myogenic, endothelial, neurogenic, and hepatic pathways. Induced differentiation along multiple pathways was documented by the expression of mRNAs for lineage-specific genes. Multilineage differentiation was characteristic of AFS Cells that were cloned by limiting dilution. Studies based on marking with a retroviral vector confirmed that cloned AFS Cells and their differentiated derivatives did in fact descend from a single Cell, and that the AFS Cells are pluripotent Stem Cells. Feeders were not necessary for the undifferentiated AFS Cells to expand extensively. The Cells doubled in 36 hours and were not tumorigenic. Lines maintained for more than 250 population doublings continued to have long telomeres and normal karyotypes. The differentiated Cells derived from AFS Cells included neuronal lineage Cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage Cells producing urea, and osteogenic lineage Cells that formed tissue-engineered bone. These studies affirm that Stem Cells capable of extensive self-renewal can routinely be obtained from human Amniotic fluid. AFS Cells can serve as precursors to a broad range of differentiated Cell types that potentially have therapeutic applications. Banking of Cells that would otherwise be discarded could provide a convenient source not only for autologous treatment later in life, but for matching of histocompatible donor Cells with prospective recipients.

  • isolation of Amniotic Stem Cell lines with potential for therapy
    Nature Biotechnology, 2007
    Co-Authors: Paolo De Coppi, Laura Perin, Georg Bartsch, Minhaj M Siddiqui, Tao Xu, Cesar C Santos, Gustavo Mostoslavsky, Angeline C Serre, Evan Y Snyder, James J Yoo
    Abstract:

    Stem Cells capable of differentiating to multiple lineages may be valuable for therapy. We report the isolation of human and rodent Amniotic fluid‐derived Stem (AFS) Cells that express embryonic and adult Stem Cell markers. Undifferentiated AFS Cells expand extensively without feeders, double in 36 h and are not tumorigenic. Lines maintained for over 250 population doublings retained long telomeres and a normal karyotype. AFS Cells are broadly multipotent. Clonal human lines verified by retroviral marking were induced to differentiate into Cell types representing each embryonic germ layer, including Cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. Examples of differentiated Cells derived from human AFS Cells and displaying specialized functions include neuronal lineage Cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage Cells producing urea, and osteogenic lineage Cells forming tissue-engineered bone. Amniotic fluid is known to contain multiple Cell types derived from the developing fetus 1,2 . Cells within this heterogeneous population can give rise to diverse differentiated Cells including those of adipose, muscle, bone and neuronal lineages 3‐6 . We now describe lines of broadly multipotent AFS Cells, and use retroviral marking to verify that clonal human AFS Cells can give rise to adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic lineages, inclusive of all embryonic germ layers. In this respect, they meet a commonly accepted criterion for pluripotent Stem Cells, without implying that they can generate every adult tissue. Neurons, hepatocytes and osteoblasts are among the Cell types for which improved Stem Cell sources may open up novel therapeutic applications. For each of these examples we show that AFS Cells can yield differentiated Cells that express lineage-specific markers and acquire characteristic functions in vitro. In addition, we present initial studies indicating that AFS Cells induced toward particular lineages can generate specialized Cells after implantation in vivo .W e show that AFS Cells directed to neural lineage differentiation by exposure to nerve growth factor (NGF) are able to widely engraft the developing mouse brain in a manner similar to that observed previously for neural Stem Cells 7 . In addition, we document the formation of tissueengineered bone from printed constructs of osteogenically differentiated human AFS Cells in immune-deficient mice. RESULTS Clonal Stem Cell lines from Amniotic fluid Approximately 1% of the Cells in cultures of human amniocentesis specimens obtained for prenatal genetic diagnosis express the surface

Khalpey Zain - One of the best experts on this subject based on the ideXlab platform.

  • A dual therapy of off-pump temporary left ventricular extracorporeal device and Amniotic Stem Cell for cardiogenic shock
    'Springer Science and Business Media LLC', 2017
    Co-Authors: Kazui Toshinobu, Tran, Phat L., Pilikian, Tia R., Marsh, Katie M., Runyan Raymond, Konhilas John, Smith Richard, Khalpey Zain
    Abstract:

    Background: Temporary mechanical circulatory support device without sternotomy has been highly advocated for severe cardiogenic shock patient but little is known when coupled with Amniotic Stem Cell therapy. Case presentation: This case reports the first dual therapy of temporary left ventricular extracorporeal device CentriMag with distal banding technique and human Amniotic Stem Cell injection for treating a severe refractory cardiogenic shock of an 68-year-old female patient. A minimally-invasive off-pump LVAD was established by draining from the left ventricle and returning to the right axillary artery with distal arterial banding to prevent right upper extremity hyperperfusion. Amniotic Stem Cells were injected intramyocardially at the left ventricular apex, lateral wall, inferior wall, and right subclavian vein. Conclusion: The concomitant use of the temporary minimally-invasive off-pump CentriMag placement and Stem Cell therapy not only provided an alternative to cardiopulmonary bypass and full-median sternotomy procedures but may have also synergistically enhanced myocardial reperfusion and regeneration.This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu